{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:12Z","timestamp":1787026572403,"version":"build-2736575974"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031665","name":"Medical Research Center, Hamad Medical Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have significantly improved the therapeutic landscape of multiple malignancies. It becomes critical to understand the incidence, profile, and consequences of immune-related adverse events (irAEs) within real-world populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>We aimed to assess the safety profile of ICIs in adult cancer patients at the National Center for Cancer Care and Research (NCCCR), Qatar, and explore the factors associated with irAEs, including the impact of irAEs on the survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included adult cancer patients who received at least one dose of an ICI between January 1, 2015, and January 1, 2020. Data was collected from electronic health records and institutional adverse drug reaction (ADR) reporting systems. irAEs were graded using Common terminology criteria of adverse events, version 5 (CTCAE v5). Logistic regression analysis was used to evaluate factors associated with irAEs. Kaplan\u2013Meier and landmark analysis assessed associations between irAEs and progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n                    <jats:p>Approvals were obtained from HMC IRB (MRC-01-20-251) and Qatar University IRB (073\/2025-EM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 236 patients (median age 57 years, 72% male) were included. Most patients had advanced solid tumors, with thoracic malignancies being the most common.<\/jats:p>\n                    <jats:p>Pembrolizumab was the predominant agent used. irAEs occurred in 55.9% of patients, with the most frequent side effects being endocrine (26.4%), dermatologic (13.5%), and hepatic (12.4%) toxicities. Sixteen patients (6.8%) experienced fatal irAEs, with pneumonitis being the most common cause of death.<\/jats:p>\n                    <jats:p>The median time to onset of irAEs was 55 days (IQR 16\u2010129.5 days). Most events occurred in the acute phase (21\u2013180 days post-treatment). Resolution rates of irAEs varied, with gastrointestinal irAEs resolving in 92% of cases, compared to 40% for hematological events. Pulmonary irAEs were associated with the highest rate of treatment discontinuation.<\/jats:p>\n                    <jats:p>\n                      Factors associated with irAEs included a higher number of ICI treatment cycles (p=0.019), lower baseline and six-week platelet counts (p=0.015 and p=0.012, respectively), and elevated baseline TSH (p=0.048). In multivariable regression analysis, the only factor that remained statistically significant was the number of treatment cycles (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.004).\n                    <\/jats:p>\n                    <jats:p>Dermatologic irAEs were significantly more common among patients aged \u226565 years (17.9% vs. 7.1%, p=0.018). Patients with poor performance status (PS \u2265 2) experienced a significantly higher rate of cardiac irAEs compared to those with good PS (10.9% vs. 1.7%, p=0.036).<\/jats:p>\n                    <jats:p>\n                      In the 30-day landmark analysis, patients who developed irAEs had significantly worse PFS (3.3 vs. 7.1 months, p=0.0085) and OS (4.37 vs. 9.0 months, p=0.0004) compared to those without irAEs. These finding were confirmed using adjusted landmark analysis where irAEs were associated with worse OS (HR 2.13, 95% CI 1.34\u20133.3,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001) and PFS (HR 1.88, 95% CI 1.22\u20132.87,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004). Additionally, time-dependent Cox regression also demonstrated worse OS (HR 1.86, 95% CI 1.23\u20132.79,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003) and PFS (HR 1.96, 95% CI 1.41\u20132.72,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort, irAEs were frequent and clinically diverse. Using adjusted landmark analysis and time-dependent Cox regression, early-onset irAEs were associated with inferior survival in our cohort. Poor baseline PS was linked to an increased risk of cardiac irAEs. Older adults were at a higher risk of dermatological irAEs. Some factors such as higher number of ICI treatment cycles, thrombocytopenia and elevated TSH at baseline may aid in risk stratification. These findings reinforce the need for timely detection and multidisciplinary management of irAEs to optimize ICI safety and effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1665716","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:48:56Z","timestamp":1761720536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)"],"prefix":"10.3389","volume":"16","author":[{"given":"Nabil E.","family":"Omar","sequence":"first","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"Clinical and Population Health Research Program, College of Pharmacy, QU Health, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Elazzazy","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"College of Pharmacy, QU Health, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Hamad","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"College of Pharmacy, QU Health, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Omar","family":"Saad","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Al Wakra Hospital, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Alasmar","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar M.","family":"Nasser","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Benkhadra","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebatalla M.","family":"Afifi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah I.","family":"Jibril","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan A.","family":"Dawoud","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Hamid","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afnan","family":"Alnajjar","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa O.","family":"Sahal","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal","family":"Gulied","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Elewa","sequence":"additional","affiliation":[{"name":"College of Pharmacy, QU Health, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy: Revitalizing a suppressed immune system","volume":"21","author":"Pico de Coa\u00f1a","year":"2015","journal-title":"Trends Mol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0002","article-title":"Immune checkpoint inhibitor combinations in solid tumors: Opportunities and challenges","volume":"8","author":"Kyi","year":"2016","journal-title":"Immunotherapy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"31","author":"Magee","year":"2020","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2020","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","article-title":"Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer","volume":"79","author":"Gaynor","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1758835920937612","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481?download=true","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1608","DOI":"10.1016\/j.annonc.2024.10.597","article-title":"571P The economic sequelae of immune related adverse events secondary to immune checkpoints inhibitors in Qatar: A hospital-perspective analysis","volume":"35","author":"Omar","year":"2024","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2002","DOI":"10.1002\/onco.13918","article-title":"Real-world clinical and economic outcomes in selected immune-related adverse events among patients with cancer receiving immune checkpoint inhibitors","volume":"26","author":"Zheng","year":"2021","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B19","article-title":"The flip of the coin of personalized cancer immunotherapy: A focused review on rare immune checkpoint related adverse effects","volume-title":"Immune Checkp Inhib - New Insights Recent Prog","author":"Omar","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180648","article-title":"Hematological toxicity of immune checkpoint inhibitors: real-world retrospective outcomes from a cohort study in Qatar","volume":"142","author":"Benkhadra Pharm","year":"2023","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01354","article-title":"Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: A systematic review","volume":"11","author":"Omar","year":"2020","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S223616","article-title":"Pancytopenia and limbic encephalopathy complicating immunotherapy for clear cell endometrial cancer with microsatellite instability-high (MSI-H)","volume":"12","author":"Kanbour","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02726-1","article-title":"Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review","volume":"70","author":"Suliman","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7142","article-title":"CLO19-045: safety of immune checkpoint inhibitors in cancer patients with microsatellite instability-high (MSI-H) status: an experience from Qatar","volume":"17","author":"Omar","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000532100","article-title":"Pembrolizumab-induced rhabdomyolysis in a clear cell renal cell carcinoma patient: A case report","volume":"16","author":"Altermanini","year":"2023","journal-title":"Case Rep Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1453429","article-title":"Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e252668","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor\u00a0response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1545-8","article-title":"Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma","volume":"63","author":"Simeone","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5919","article-title":"Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities","volume":"12","author":"Mehra","year":"2023","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis","volume":"70","author":"Guzman-Prado","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.07.007","article-title":"Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab","volume":"88","author":"Fujisawa","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01229-w","article-title":"Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): A large retrospective multicenter study","volume":"37","author":"Russo","year":"2020","journal-title":"Adv Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26609","article-title":"Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel","volume":"233","author":"Russo","year":"2018","journal-title":"J Cell Physiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22964","article-title":"Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"33","author":"Liu","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.04.045","article-title":"Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy","volume":"153","author":"Dearden","year":"2021","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01219-7","article-title":"Hyperacute Multisystem Toxicities with Immune Checkpoint Inhibitors in the FDA Adverse Event Reporting System: The Immune\u2212Adversome [abstract]. Poster P006 presented at: 21st ISoP Annual Meeting \u201cA New Era of Pharmacovigilance: Challenges and Op","volume":"45","author":"Raschi","year":"2022","journal-title":"Drug Saf"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.ekir.2020.08.002","article-title":"Hyperacute onset of immune checkpoint inhibitor\u2013related acute interstitial nephritis","volume":"5","author":"Tawhari","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: A pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1163768","article-title":"Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis","volume":"13","author":"Anpalakhan","year":"2023","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2024","journal-title":"Br J Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-018-0421-z","article-title":"Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious\/fatal adverse events","volume":"6","author":"Zhao","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for Malignancies: A meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"B62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40257-023-00775-7","article-title":"Features and long-term outcomes of stage IV melanoma patients achieving complete response under anti-PD-1-based immunotherapy","volume":"24","author":"Chatziioannou","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.849","article-title":"Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort","volume":"86","author":"Carlet","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"106628","DOI":"10.1016\/j.intimp.2020.106628","article-title":"Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors","volume":"85","author":"Yao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/cancers16061225","article-title":"Non-invasive predictive biomarkers for immune-related adverse events due to immune checkpoint inhibitors","volume":"16","author":"Ponvilawan","year":"2024","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/immuno1030017","article-title":"Eosinophil count as predictive biomarker of immune-related adverse events (irAEs) in immune checkpoint inhibitors (ICIs) therapies in oncological patients","volume":"1","author":"Giommoni","year":"2021","journal-title":"Immuno"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2022.2104132","article-title":"C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients","volume":"61","author":"Kankkunen","year":"2022","journal-title":"Acta Oncol (Madr)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-85","article-title":"High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study","volume":"15","author":"Onodera","year":"2023","journal-title":"J Thorac Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268288","article-title":"Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis","volume":"17","author":"Wang","year":"2022","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618570","article-title":"Absolute lymphocyte count predicts immune-related adverse events in patients with non-small-cell lung cancer treated with nivolumab monotherapy: A multicenter retrospective study","volume":"11","author":"Egami","year":"2021","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03798-6","article-title":"The role of tumor types in immune-related adverse events","volume":"27","author":"Xu","year":"2025","journal-title":"Clin Trans Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173045","article-title":"Immune-related adverse events of genitourinary cancer patients, a retrospective cohort study","volume":"16","author":"Hunting","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1196793","article-title":"Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"14","author":"Feng","year":"2023","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000001295","article-title":"Immunotherapy toxicities in genito-urinary cancers: insights and challenges for clinicians","volume":"35","author":"Mercinelli","year":"2025","journal-title":"Curr Opin Urol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis","volume":"70","author":"Guzman-Prado","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i2.103","article-title":"Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses","volume":"12","author":"Peravali","year":"2021","journal-title":"World J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e21115","article-title":"Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors","volume":"40","author":"Resnick","year":"2022","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae279","article-title":"The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients","volume":"30","author":"Radwan","year":"2025","journal-title":"Oncologist"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab035","article-title":"Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy","volume":"113","author":"Jing","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-71746-z","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"14","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071054","article-title":"Sex-related differences in immunotherapy toxicities: insights into dimorphic responses","volume":"17","author":"Canzian","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: A real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.885","article-title":"Female\u00a0sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort study","volume":"87","author":"Bui","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae279","article-title":"Immune-related adverse events and efficacy - the more it hurts, the better it works","volume":"7","author":"Zhang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07142-3","article-title":"Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody","volume":"20","author":"Matsuoka","year":"2020","journal-title":"BMC Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"28309","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: A systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","article-title":"Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: A multicenter retrospective study","volume":"41","author":"Okada","year":"2019","journal-title":"Clin Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708195","article-title":"Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 inhibitors: A systematic review and meta-analysis","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.07.003","article-title":"Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1\/PD-L1 therapy","volume":"45","author":"Shafqat","year":"2018","journal-title":"Semin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.479","article-title":"Clinical impact on treatment effectiveness of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"42","author":"Suzuki","year":"2024","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1758835920980546","DOI":"10.1177\/1758835920980546","article-title":"The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis","volume":"12","author":"Xu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non\u2013small-cell lung cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1080\/1750743X.2025.2492541","article-title":"Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events","volume":"17","author":"Nurmela","year":"2025","journal-title":"Immunotherapy"},{"key":"B99","doi-asserted-by":"publisher","first-page":"708195","DOI":"10.1016\/j.lungcan.2025.108555","article-title":"Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens","volume":"204","author":"Sugai","year":"2025","journal-title":"Lung Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-299","article-title":"Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis","volume":"13","author":"Huang","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-SITC2024.1163","article-title":"1163 Impact of timing of pneumonitis and colitis immune-related adverse events on survival in cancer patients receiving immune checkpoint inhibitors","volume-title":"BMJ","author":"Sayer","year":"2024"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0179","article-title":"Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A meta-analysis","volume":"13","author":"Dall\u2019Olio","year":"2021","journal-title":"Immunotherapy"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102452","article-title":"Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias","volume":"110","author":"Kfoury","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0636","article-title":"Hyperprogression and immune checkpoint inhibitors: hype or progress","volume":"25","author":"Adashek","year":"2020","journal-title":"Oncologist"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03323-9","article-title":"Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study","volume":"81","author":"Wu","year":"2023","journal-title":"Endocrine"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline TSH level is associated with risk of anti\u2013PD-1\u2013induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cancers16112159","article-title":"Real-world prevalence and tolerability of immune-related adverse events in older adults with non-small cell lung cancer: A multi-institutional retrospective study","volume":"16","author":"Matsukane","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01055-8","article-title":"Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"23","author":"Yang","year":"2023","journal-title":"Clin Exp Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf008","article-title":"Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"54","author":"Esen","year":"2025","journal-title":"Age Ageing"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.619385","article-title":"Age-associated changes in adverse events arising from anti-PD-(L)1 therapy","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"S690","DOI":"10.1016\/j.annonc.2023.09.2290","article-title":"1156P Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome","volume":"34","author":"Elleb\u00e6k","year":"2023","journal-title":"Ann Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/jac5.1986","article-title":"2024 ACCP virtual poster symposium May 21 - 22, 2024","volume":"7","author":"Samani","year":"2024","journal-title":"JACCP J Am Coll Clin Pharm"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1903","article-title":"Tues-93. Immune checkpoint inhibitors related adverse events in cancer patients with good versus poor performance status: A realworld nationwide retrospective analysis, 2023 ACCP Annual Meeting November 11 -;14, 2023","volume":"6","author":"Omar","year":"2023","journal-title":"JACCP J Am Coll Clin Pharm"},{"key":"B117","doi-asserted-by":"publisher","first-page":"13217","DOI":"10.1007\/s10238-023-01055-8","article-title":"Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study","volume":"12","author":"Olsson Ladjevardi","year":"2023","journal-title":"Cancer Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"afaf008","DOI":"10.1016\/j.jgo.2024.101742","article-title":"Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper","volume":"15","author":"Guven","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"104259","DOI":"10.1016\/j.critrevonc.2024.104259","article-title":"Geriatric predictors of response and adverse events in older\u00a0patients with cancer treated with immune checkpoint inhibitors: A systematic review","volume":"194","author":"\u00d6zkan","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2017","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1902412","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1665716\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:51:44Z","timestamp":1781862704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1665716\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":121,"alternative-id":["10.3389\/fimmu.2025.1665716"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1665716","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1665716"}}